Under de senaste sex månaderna har bolaget genomfört tre exits; Blackbuck, Gringo och Juspay, vilket...
We cut '25e-'27e adj. EBITA by 13-1% Gross profit per consultant at normal levels in '26e '25e EV/EB...
We trim '25e-'27e ARR by 1-3% on continued macro weakness Volume-based revenue growth could pick up ...
FX-driven estimate changes Direct tariff impact likely minor NTM EV/EBIT of just below 7x What to l...
Q1e sales flat q-o-q, slight margin improvement to 5.
Enersense could release new financial targets as a pure service company on 28 April.
Q1 report Thursday, 24 April at 12:00 CET '25e-'27e EBITA down 3%; 6% CAGR in '24-'27e 11-9x EBITA i...
Analysguiden räknar med en fortsatt fallande vinst under Q1 2025 primärt drivet av en svagare margin...
Redeye leaves its initial comments on Nanologica's Q1 report which came in largely as expected showi...
Redeye gives a short initial comment on the positive news that Leqembi has been approved in the EU.
Beijer Alma inleder året med tre nya förvärv och inför Q1-rapporten räknar Analysguiden med en stabi...
Ahead of Atria's Q1 report, we keep our group estimates largely intact.
Q-linea has improved access to growth capital and recently advanced the ASTar launch in Europe , the...
Redeye comments on Faron’s announcement that the phase II BEXMAB trial has met its primary endpoint ...
Redeye comments on the updated clinical guidelines regarding the use of LITT in patients with metast...